FDA Accepts LEQEMBI® IQLIKTM Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review Life Science Investing
FDA Accepts LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review Life Science Investing
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares Life Science Investing
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million Biotech Investing
FDA Approves Compassionate Use of Urcosimod for the Treatment of Neuropathic Corneal Pain Life Science Investing
Cizzle Brands Partners with NHL MVP Nathan MacKinnon and USA Hockey to Launch Two New Iconic Flavours of CWENCH Hydration; Announces Results of Annual General Meeting Biotech Investing
